Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Gauckler, P; Shin, JI; Alberici, F; Audard, V; Bruchfeld, A; Busch, M; Cheung, CK; Crnogorac, M; Delbarba, E; Eller, K; Faguer, S; Galesic, K; Griffin, S; van den Hoogen, MWF; Hrušková, Z; Jeyabalan, A; Karras, A; King, C; Kohli, HS; Mayer, G; Maas, R; Muto, M; Moiseev, S; Odler, B; Pepper, RJ; Quintana, LF; Radhakrishnan, J; Ramachandran, R; Salama, AD; Schönermarck, U; Segelmark, M; Smith, L; Tesař, V; Wetzels, J; Willcocks, L; Windpessl, M; Zand, L; Zonozi, R; Kronbichler, A; RITERM study group.
Rituximab in Membranous Nephropathy.
Kidney Int Rep. 2021; 6(4): 881-893. Doi: 10.1016/j.ekir.2020.12.035 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Eller Kathrin
Odler Balazs
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies, including 3 randomized controlled trials, in which complete and partial remission of proteinuria was achieved in approximately two-thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for MN, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of "the new standard." © 2021 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.

Find related publications in this database (Keywords)
B cells
membranous nephropathy
nephrotic syndrome
rituximab
© Med Uni Graz • Impressum